For decades, clinical trials required patients to travel repeatedly to a research site, an enormous burden that limited who could take part and made recruitment and retention a constant struggle. Decentralized clinical trials flip that model, bringing the trial to the patient instead. Done well, they can widen access, speed enrollment, and keep participants engaged. Done carelessly, they add complexity without benefit. Here is what they are and how to approach running one.
What a decentralized trial actually is
A decentralized clinical trial (DCT) conducts some or all of its activities remotely, away from the traditional research site, using technology and local services to reach participants where they are. Instead of requiring every visit to happen at a central hospital, a DCT might use telehealth visits, wearable sensors and remote monitoring, electronic consent and electronic patient-reported outcomes, home health visits by traveling nurses, and direct-to-patient shipment of the investigational drug. In practice, most trials are not fully virtual but hybrid, keeping some in-person elements while decentralizing others, which is usually the pragmatic sweet spot.
Why decentralization is worth the effort
The appeal is substantial when the approach fits. Decentralization can dramatically improve recruitment, because patients no longer need to live near a research site to participate, widening the pool. It improves retention, since reducing the travel burden makes people far more likely to stay enrolled. It can improve diversity, reaching populations historically excluded by geography or the demands of frequent site visits, which produces evidence that better reflects the real world. And remote monitoring can generate richer, more continuous real-world data than periodic site visits ever could. For the right trial, these are not marginal gains; they can be the difference between a study that enrolls and one that stalls.
The challenges to plan for
Decentralization is not free of difficulty, and pretending otherwise leads to trouble. The regulatory and quality requirements still fully apply, and running procedures remotely raises real questions about data integrity, patient safety oversight, and consistency that must be carefully addressed. Data integration is a genuine hurdle, since pulling information from telehealth, wearables, home visits, and multiple systems into one clean, reliable dataset is technically demanding. There is a technology burden on patients and staff, and poor usability can undermine the whole approach. And critically, not every trial suits decentralization, studies requiring complex procedures, specialized equipment, or intensive in-person monitoring may need to stay largely site-based. Matching the approach to the trial is essential.
How to approach running one
A practical path makes decentralization an asset rather than a source of chaos.
- Start hybrid, and decentralize deliberately. Rather than aiming for a fully virtual trial, identify which specific elements genuinely benefit from being remote, a telehealth follow-up here, remote monitoring there, and keep in person what needs to be.
- Choose the right endpoints and procedures. Decentralization works best when the trial’s key measurements can be captured reliably at home or remotely. Design with that in mind from the start rather than retrofitting.
- Build the right technology and vendor stack. Select platforms and service providers with real DCT experience, and prioritize usability, because a system patients and sites cannot use easily will fail regardless of its features.
- Plan data integration early. Decide upfront how data from all the remote sources will flow into a single, clean, compliant dataset, rather than discovering integration problems mid-study.
- Engage regulators and plan for oversight. Address safety monitoring, data integrity, and compliance in your design, and align with regulatory expectations before you launch.
- Support the patient experience. The whole point is to reduce burden, so invest in clear instructions, responsive support, and a genuinely easy experience for participants.
The mindset that makes it work
The most successful teams treat decentralization as a means, not an end. The goal is not to run the most virtual trial possible; it is to run a better trial, one that enrolls faster, retains participants, produces high-quality data, and reaches the right patients. Decentralized elements are tools to serve that goal, deployed where they help and left aside where they do not. Approached that way, with clear thinking about what to decentralize and disciplined execution on technology, data, and compliance, a decentralized or hybrid trial can meaningfully outperform the old site-only model.
The vendor ecosystem that makes it possible
One reason decentralized trials have become practical is that a whole ecosystem of specialized providers now supplies the pieces, so sponsors no longer have to build everything themselves. Understanding the categories helps you assemble the right stack. There are platforms for electronic consent that let participants enroll and consent remotely, and for electronic patient-reported outcomes that capture how patients feel and function through apps and devices. There are remote monitoring and wearable providers whose sensors stream continuous physiological data, and telehealth systems for virtual visits. There are home health networks that send nurses to patients for procedures that must be done in person but do not require a site, and direct-to-patient logistics providers that ship investigational drugs to participants’ homes under proper conditions. And increasingly there are integrated platforms that try to tie many of these together, along with technology-forward CROs built around decentralized designs. The key insight is that these capabilities, which once sounded futuristic, are now mainstream and well supported, which is exactly why hybrid and decentralized approaches have moved from novelty to standard practice for suitable trials. When you plan a decentralized study, much of the work is selecting and integrating the right providers for the specific elements you want to decentralize, rather than inventing the tools yourself. Choosing vendors with genuine track records, and thinking early about how their systems will connect into one clean dataset, is the practical heart of making a decentralized trial actually work.
Is a decentralized approach right for your study?
The most important decision comes before any of the tactics: honestly assessing whether, and how much, your particular trial should be decentralized. The answer depends on the nature of the study. Trials whose key assessments can be captured reliably at home or remotely, and whose patient population would benefit from reduced travel, are strong candidates, and decentralizing them can transform recruitment and retention. Trials that require complex procedures, specialized equipment, or intensive in-person safety monitoring may need to stay largely site-based, and forcing decentralization onto them adds risk without reward. Most studies fall somewhere in between, which is why the hybrid model, decentralizing the elements that genuinely benefit while keeping in person what must be, is usually the pragmatic answer. The practical exercise is to go through your protocol activity by activity and ask, for each one, whether it can be done remotely without compromising data quality or patient safety, and whether doing so would meaningfully reduce burden. That assessment, done honestly and early, tells you what your trial should actually look like, and it prevents both the mistake of clinging to an all-site model out of habit and the opposite mistake of chasing a fully virtual trial that your study cannot support. Let the design follow the science and the patients, not the trend, and decentralization becomes a genuine advantage rather than a source of avoidable complexity.
Why this matters beyond any single trial
There is a bigger reason to get comfortable with decentralized and hybrid methods: they are steadily becoming the default rather than the exception, and fluency with them is now part of running trials well. The tools are mature, the providers are capable, and regulators are increasingly familiar with remote elements, so the question for most sponsors is no longer whether to use these approaches at all but which parts of each study to decentralize. Teams that understand how to design, staff, and execute hybrid trials, and how to weave the technology and vendors into one clean, compliant operation, will run faster, more inclusive, and more patient-friendly studies than those still defaulting to the old site-only model. Building that capability now, deliberately and with the right partners, is an investment that pays off across every trial that follows.
To find the platforms and providers that enable decentralized and hybrid trials, browse the BioMed Nexus clinical trial technology directory, and for background on how trials are structured, see our guide to the clinical trial phases.
Frequently asked questions
What is a decentralized clinical trial?
A decentralized clinical trial conducts some or all of its activities remotely, away from a traditional research site, using tools like telehealth visits, wearable sensors, electronic consent, home health visits and direct-to-patient drug shipment. Most are hybrid, keeping some in-person elements while decentralizing others, which brings the trial to the patient rather than requiring constant travel.
What are the benefits of decentralized clinical trials?
Decentralization can improve recruitment by removing the need to live near a site, improve retention by reducing travel burden, improve diversity by reaching historically excluded populations, and generate richer real-world data through continuous remote monitoring. For the right trial, these gains can be the difference between a study that enrolls and one that stalls.
What are the challenges of running a decentralized trial?
Key challenges include meeting full regulatory and quality requirements while running procedures remotely, integrating data from many sources into one clean dataset, the technology burden on patients and staff, and the fact that not every trial suits decentralization, some require complex procedures or intensive in-person monitoring. Matching the approach to the trial is essential.
